Results 11 to 20 of about 10,258 (173)
NKG2A inhibits TH2 cell effector function
BMC Pulmonary Medicine, 2007 Background We previously reported that NKG2A, a key inhibitory ligand for HLA-E, is expressed on activated TH2 but not TH1 cells. Here we measured cytokine expression in human ex vivo TH2 cells upon activation with anti-CD3/28 and challenge with an NKG2A-
Mojgani Bahar +4 more
doaj +3 more sources
High Metabolic Function and Resilience of NKG2A-Educated NK Cells [PDF]
Frontiers in Immunology, 2020 Natural killer (NK) cells are an important component of the innate immune system for the control of intracellular pathogens and cancer cells. NK cells demonstrate heterogeneous expression of inhibitory surface receptors.
Andrew J. Highton +9 more
doaj +3 more sources
NKG2A, a New Kid on the Immune Checkpoint Block [PDF]
Cell, 2018 One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8+ T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.
John B, Haanen, Vincenzo, Cerundolo
openaire +2 more sources
KIR+CD8+ and NKG2A+CD8+ T cells are distinct innate-like populations in humans
Cell Reports, 2023 Summary: Subsets of the human CD8+ T cell population express inhibitory NK cell receptors, such as killer immunoglobulin-like receptors (KIRs) and NKG2A.
Seong Jin Choi +7 more
doaj +1 more source
Analytical Cellular Pathology, 2023 Background. NKG2A (KLRC1) belongs to the NKG2 family, which has been shown to affect the activity of natural killer (NK) cells and CD8T cells. However, a comprehensive biological analysis and exploration of NKG2A in different cancers is lacking and this ...
Yao Rong +10 more
doaj +1 more source
Decrease of peripheral and intestinal NKG2A-positive T cells in patients with ulcerative colitis. [PDF]
PLoS ONE, 2012 To investigate the role of inhibitory natural killer receptors (iNKRs) in inflammatory bowel disease (IBD), we analyzed the expression of NKG2A, one of the iNKRs, on T cells in a mouse colitis model and human IBD.
Takehiko Katsurada +10 more
doaj +1 more source
Monalizumab: inhibiting the novel immune checkpoint NKG2A [PDF]
Journal for ImmunoTherapy of Cancer, 2019 The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhibition signals on T cells.
Hall, T. van +8 more
openaire +5 more sources
Cell Therapy Using Anti-NKG2A Pretreated Natural Killer Cells in Patients with Hepatocellular Carcinoma [PDF]
Advanced Pharmaceutical BulletinPurpose: The activities and functions of natural killer (NK) cells are regulated by a limited repertoire of activating and inhibitory receptors. Thus, we provided a study of inhibition of the NKG2A using monoclonal antibodies (mAbs), and as a primary ...
Shirin Tavakoli +10 more
doaj +1 more source
The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment [PDF]
Clinical Cancer Research, 2020 AbstractThe success of checkpoint blockade therapy revolutionized cancer treatment. However, we need to increase the fraction of responding patients and overcome acquired resistance to these therapies. Recently, the inhibitory receptor NKG2A received attention as a new kid on the block of immune checkpoints.
Borst, L. +2 more
openaire +3 more sources
Frontiers in Immunology, 2018 Natural killer (NK) cell-based immunotherapy is a promising therapy for cancer patients. Inhibitory killer immunoglobulin-like receptors (KIRs) and NKG2A are required for NK cell licensing, but can also inhibit NK cell effector function.
Niken M. Mahaweni +14 more
doaj +1 more source